Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/05/23
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial ResultsGlobeNewsWire • 05/04/23
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023GlobeNewsWire • 04/11/23
Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology ConferenceGlobeNewsWire • 03/29/23
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/10/23
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/09/23
Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the LiverGlobeNewsWire • 02/16/23
Aligos Therapeutics to Present at the SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/10/23
Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024GlobeNewsWire • 02/08/23
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009GlobeNewsWire • 01/05/23
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)GlobeNewsWire • 12/14/22
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD's The Liver Meeting® 2022GlobeNewsWire • 11/04/22
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/02/22
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD's The Liver Meeting® 2022GlobeNewsWire • 10/21/22
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute's 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MAGlobeNewsWire • 10/18/22
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755GlobeNewsWire • 10/14/22
Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory FraudGlobeNewsWire • 09/28/22
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/04/22
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial ResultsGlobeNewsWire • 05/04/22